Predilife SA
EEURONEXT:ALPRE1.01
EUR
+0.16
(+18.82%)
ISIN
FR0010169920
Return %
Stock
S&P 500
1Y
-67.83
13.14
3Y
-82.88
80.78
5Y
-85.47
67.74
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Stéphane Ragusa
- Full Time Employees
- 21
- Sector
- Technology services
- Industry
- Packaged software
- Address
- 39, Rue Camille Desmoulins Villejuif IF France 94805
- IPO Date
- Dec 21, 2018
- Website
- predilife.com
- Similar Companies
- Business
- Predilife S.A. (ALPRE.PA) develops and markets predictive medicine solutions that combine genetic tests, medical imaging, artificial intelligence, and big data to assess individual risk profiles for serious diseases including breast, prostate, lung, colorectal cancers, melanoma, and cardiovascular conditions. The company offers core products such as MammoRisk, a predictive check-up for breast cancer risk over five years with personalized follow-up recommendations; Predictive Check-Up for Multiple Conditions covering cancers and cardiovascular risks for men and women; and DenSeeMammo, a software for breast density measurement; targeting businesses, insurance companies, brokers, healthcare professionals, and individuals primarily through remote, cost-effective digital platforms. Founded in 2004 by Stéphane Ragusa and headquartered in Villejuif, France, Predilife operates in Europe with certifications from ANSM, CE marking, and MHRA registration, and listed on Euronext Growth Paris since 2018. Recent developments include the 2024 spin-off of its MammoRisk subsidiary, completion of an 8.5% convertible bond issuance maturing July 2029 for financing, expansion of predictive offerings since 2021 to multiple cancers and cardiovascular disease, release of 2025 half-year financial results in October, and ongoing partnerships with major cancer databases and clinics such as the American Hospital of Paris.